4//SEC Filing
Godward Donna 4
Accession 0001062993-23-015060
CIK 0001842939other
Filed
Jul 17, 8:00 PM ET
Accepted
Jul 18, 8:39 PM ET
Size
16.7 KB
Accession
0001062993-23-015060
Insider Transaction Report
Form 4
Godward Donna
Chief Quality Officer
Transactions
- Award
Common Stock
2023-07-14+37,296→ 37,296 total - Award
Stock Option (right to buy)
2023-07-14+5,318→ 5,318 totalExercise: $2.27Exp: 2029-07-19→ Common Stock (5,318 underlying) - Award
Stock Option (right to buy)
2023-07-14+12,309→ 12,309 totalExercise: $2.11Exp: 2032-07-13→ Common Stock (12,309 underlying) - Award
Stock Option (right to buy)
2023-07-14+12,309→ 12,309 totalExercise: $2.60Exp: 2032-12-15→ Common Stock (12,309 underlying) - Award
Stock Option (right to buy)
2023-07-14+2,090→ 2,090 totalExercise: $1.79Exp: 2027-06-20→ Common Stock (2,090 underlying) - Award
Stock Option (right to buy)
2023-07-14+119,098→ 119,098 totalExercise: $2.11Exp: 2031-09-23→ Common Stock (119,098 underlying)
Footnotes (7)
- [F1]On July 14, 2023, Alpha Healthcare Acquisition Corp. III ("ALPA") consummated a business combination (the "Business Combination") by and among ALPA, Candy Merger Sub, Inc., a Delaware Corporation ("Merger Sub") and Carmell Regen Med Corporation, a Delaware corporation ("Legacy Carmell"), ALPA changed its name to "Carmell Therapeutics Corporation" and Merger Sub merged with and into Legacy Carmell. As part of the Business Combination, each share of common stock of Legacy Carmell was exchanged for 0.06154 shares of common stock of Carmell Therapeutics Corporation.
- [F2]Options are fully vested and exercisable.
- [F3]Options to purchase 5,318 shares of common stock of Legacy Carmell granted on July 19, 2019, which vest as follows: 25% vested on July 19, 2020, July 19, 2021 and July 19, 2022 and the remaining 25% becomes vested on July 19, 2023.
- [F4]Options to purchase 119,098 shares of common stock of Legacy Carmell granted on September 23, 2021, which vest as follows: 25% vested on September 23, 2022 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date.
- [F5]Options to purchase 12,309 shares of common stock of Legacy Carmell granted on July 13, 2023 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date.
- [F6]Options to purchase 12,309 shares of common stock of Legacy Carmell granted on December 15, 2022, which vest as follows: 25% vesting on December 22, 2023 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date.
- [F7]As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation.
Issuer
ALPHA HEALTHCARE ACQUISITION CORP III
CIK 0001842939
Entity typeother
Related Parties
1- filerCIK 0001984167
Filing Metadata
- Form type
- 4
- Filed
- Jul 17, 8:00 PM ET
- Accepted
- Jul 18, 8:39 PM ET
- Size
- 16.7 KB